Analyst Susan Anderson of Canaccord Genuity maintained a Buy rating on Kenvue, Inc. (KVUE – Research Report), reducing the price target to $24.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Susan Anderson’s rating is based on Kenvue, Inc.’s ability to navigate through current challenges while making strategic improvements. Despite recent sales setbacks due to issues like distribution challenges in China and a softer cough/cold season, the company has demonstrated resilience by enhancing its gross margins and reducing operational expenses.
Additionally, management’s initiatives in brand investment are yielding positive results, particularly in the Skin, Health & Beauty segment, with brands like Neutrogena beginning to regain market traction. The ongoing efforts to strengthen major brands such as Tylenol, coupled with a strategic focus on operational efficiency and cost management, signal a promising outlook for Kenvue. Although the near-term challenges have led to a revised price target, Anderson retains a Buy rating, confident in the company’s long-term growth potential and strategic direction.